CORT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Corcept Therapeutics Inc (CORT) is not a strong buy for a beginner investor with a long-term strategy at this moment. While the company has received FDA approval for its drug Lifyorli, which is a positive catalyst, the stock is currently experiencing a downward price trend, and there are significant legal risks from class action lawsuits. Additionally, the company's financial performance shows declining net income and EPS, which may not align with the user's long-term investment goals.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 68.106, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 38.947, with key support at 31.846 and resistance at 46.048. The recent price drop of -4.79% in regular trading and -4.77% in pre-market trading indicates bearish sentiment.
FDA approval of Lifyorli for platinum-resistant ovarian cancer, which diversifies the company's portfolio beyond Korlym.
Analysts have raised price targets, with Canaccord increasing the target to $110 and maintaining a Buy rating.
Class action lawsuits alleging misleading statements about FDA concerns over relacorilant.
Recent financial performance shows a decline in net income (-21% YoY) and EPS (-26.92% YoY).
Insider and hedge fund trading trends are neutral, indicating no significant confidence from key stakeholders.
In Q4 2025, revenue increased by 11.12% YoY, showing growth. However, net income dropped by 21% YoY, and EPS declined by 26.92% YoY, reflecting profitability challenges. Gross margin improved slightly to 98.74%.
Analysts generally maintain a positive outlook, with multiple Buy ratings and increased price targets (e.g., Canaccord raised to $110). However, H.C. Wainwright lowered its price target to $60, citing concerns over legal and competitive risks.
